Will Kinase Inhibitors Have a Dark Side?
- 20 July 2006
- journal article
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 355 (3) , 313-315
- https://doi.org/10.1056/nejmcibr062354
Abstract
Small-molecule inhibitors of Akt kinase are being developed as potential therapeutic agents for cancer. However, a recent study suggests that they may promote metastasis in certain settings.Keywords
This publication has 5 references indexed in Scilit:
- mTOR Inhibition Induces Upstream Receptor Tyrosine Kinase Signaling and Activates AktCancer Research, 2006
- Inhibition of TGFβ signaling in cancer therapyCurrent Opinion in Genetics & Development, 2005
- Akt Blocks Breast Cancer Cell Motility and Invasion through the Transcription Factor NFATMolecular Cell, 2005
- Activation of Akt-1 (PKB-α) Can Accelerate ErbB-2-Mediated Mammary Tumorigenesis but Suppresses Tumor InvasionCancer Research, 2004
- Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTORProceedings of the National Academy of Sciences, 2001